Depomed Completes Enrollment for Non-Hormonal Treatment Study in Menopausal Hot Flashes
News Mar 03, 2009
Depomed, Inc. has announced that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment of menopausal hot flashes.
“We are glad that we achieved this milestone today and look forward to the results of both Breeze 1 and Breeze 2 trials in hot flashes expected later this year. We are well on plan in this important execution year for us,” said Carl A. Pelzel, president and chief executive officer of Depomed.
“DM-5689 has the potential to become a significant alternative treatment of hot flashes for the large number of menopausal women in this country. I am glad that we have achieved this milestone in our clinical study today and I would like to convey my thanks to all the Breeze 1 investigators who have made this possible. We look forward to seeing the results later this year,” added Dr. Risa Kagan, of East Bay Physicians Medical Group and Clinical Professor, Dept. Ob/Gyn, UCSF, the lead investigator for the Breeze 1 study.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018